^{Diflucan ®} it is shown for treatment of such fungal infections at adults (see the Section "Pharmacological"):

• cryptococcal meningitis (see the section "Features of Application");
• a coccidioidosis (see the section "Features of Application");
• invasive candidiasis;
• candidiasis of mucous membranes, including candidiasis of a stomatopharynx and candidiasis of a gullet, a kandiduriya, chronic candidiasis of skin and mucous membranes
• chronic atrophic candidiasis of an oral cavity (the candidiasis caused by use of dentures) at inefficiency of hygiene of an oral cavity or local therapy.

^{Diflucan ®} it is shown for prevention of such diseases at adults as:

• a recurrence of cryptococcal meningitis at patients with high risk of its development;
• a recurrence of candidiasis of a stomatopharynx or a gullet at patients with HIV with high risk of its development;
• prevention of candidosis infections at patients with a long neutropenia (for example, patients with malignant diseases of blood which receive chemotherapy, or patients at transplantation of haematopoietic stem cells) (see the section "Pharmacological properties. Pharmacological").

^{Diflucan ®} it is shown to children from the birth for treatment of candidiasis of mucous membranes (stomatopharynx candidiasis, gullet candidiasis), invasive candidiases, cryptococcal meningitis and for prevention of candidosis infections at patients with reduced immunity. Drug can be used as maintenance therapy for prevention of a recurrence of cryptococcal meningitis at children with high risk of its development (see the Section "Features of Application").

before obtaining results of cultural and other laboratory researches; however after obtaining results the anti-infectious therapy should be corrected as appropriate.

Structure

active ingredient: flukonazol / fluconazole;

1 ml 2 mg of a flukonazol;

Excipients: sodium chloride, water for injections.

Flukonazol is antifungal means of a class of triazoles. Primary mechanism of its action is suppression fungal 14 - the alpha lanosterol-demethylation mediated by P450 cytochrome that is the integral stage of biosynthesis of fungal ergosterol. Accumulation 14 - alpha methyls-sterols correlates with the subsequent loss of ergosterol a membrane of a fungal cell and can answer behind antifungal activity of a flukonazol. Flukonazol is more selection to fungal P450 cytochrome enzymes, than to various systems of enzymes of P450 cytochrome of mammals.

Contraindication

Hypersensitivity to a flukonazol, others azolny connections or to any of the excipients of medicine specified in the section "Structure".

Simultaneous application of a flukonazol and terfenadin to patients who apply flukonazol repeatedly in doses 400 mg/days and above (according to results of a research of interaction of repeated application).

by means of CYRZA4 enzyme (for example a tsizaprida, an astemizola, Pimozidum, quinidine and erythromycin) (see the Section "Features of Application" and "Interaction with Other Medicines and Other Types of Interactions").

Route of administration and doses

Dose of a flukonazol depends on a look and weight of a fungal infection.

In need of repeated use of medicine of treatment of infections before disappearance of clinical and laboratory manifestations of activity of a fungal infection. The insufficient duration of treatment can lead to resuming of active infectious process.

^{Diflucan ®} use depending on a dosage form, inside (capsules) or in a way of infusion (solution to infusions). The route of administration of medicine depends on a clinical condition of the patient. There is no need for change of a daily dose of medicine at change of a way of its application from reception on intravenous and vice versa.

Solution for infusions should be entered with a speed which is not exceeding 10 ml/min.

Compatibility of medicine.

^{Diflucan ®} it is compatible to such solutions as:

• 5% and 20% glucose solution
• Ringera solution;
• Hartman's solution;
• chloride potassium solution in glucose;
• 4.2% and 5% bicarbonate sodium solution;
• 3.5% solution to aminosyn;
• 0.9% chloride sodium solution
• dialaflex (6.36% solution for intraperitoneal dialysis).

^{Diflucan ®} can be entered into an infusional system together with one of the solutions stated above. Though cases of nonspecific incompatibility of medicine with other means are not described, it is not recommended to mix ^{Diflucan ®} with other medicines before infusion.

only for single application. Cultivation should be carried out in aseptic conditions. Solution needs to be checked for existence of foreign particles and change of coloring. Solution should be used only when it transparent and does not contain foreign particles. Unused residues of medicine need to be destroyed.

Children.

should not exceed the maximum daily dose of 400 mg.

As well as at similar infections at adults, duration of treatment depends on clinical and mycologic the answer. ^{Diflucan ®} is applied 1 time a day.

Feature of application

Use during pregnancy or feeding by a breast

Pregnancy.

according to an observation research, the increased risk of spontaneous abortion at the women getting flukonazol during the first trimester of a vagitnost.Povidomlyalosya about numerous congenital pathologies at newborns (including a brachycephaly, an auricle dysplasia, excessive increase in a front fontanel, a hip curvature, a plechopromenevy synostosis) whose mothers accepted high doses of a flukonazol (400-800 mg/days) within at least three or more months for treatment a coccidioidosis exists. Communication between application of a flukonazol and these cases it is not defined.

Children

use Drug to children from the birth, see the section "Route of Administration and Doses".

Ability to influence speed of response at control of motor transport or other mechanisms

Researches of influence of the medicine ^{Diflucan ®} on ability to steer motor transport or other mechanisms was not carried out.

Patients on a possibility of development of dizziness or court (see the Section "Side reactions") during use of the medicine ^{Diflucan ®} . At development of such symptoms it is not recommended to steer motor transport or to work with mechanisms.

Overdose

received the message about overdose flukonazoly; it was at the same time reported about hallucinations and paranoid behavior.

At overdose symptomatic maintenance therapy and if necessary to wash out a stomach.

with urine; the artificial diuresis can accelerate medicine removal. The session of a hemodialysis lasting 3:00 reduces the level of a flukonazol in blood plasma by 50%.

Side reactions

Most often (> 1/10) it was reported about such side reactions: headache, abdominal pain, diarrhea, nausea, vomiting, increase in level of alaninaminotranspherase (ALT), increase in level of aspartate aminotransferase (nuclear heating plant), increase in level of alkaline phosphatase of blood, rash.

Interaction with other medicines and other types of interactions

Contraindicated simultaneous application of a flukonazol and medicines stated below.

Tsizaprid: it was reported about development of side reactions from heart, including about Bouveret's ventricular disease like "pirouette" at patients who at the same time applied flukonazol and tsizaprid. The controlled research showed that simultaneous application of 200 mg of a flukonazol of 1 times a day and 20 mg of a tsizaprid 4 times a day led to substantial increase of level of a tsizaprid in blood plasma and lengthening of an interval of QT. Simultaneous application of a flukonazol and tsizaprid is contraindicated.

terfenadin: because of cases of development of the heavy cardiac arrhythmias caused by lengthening of an interval of QTc in the patients receiving azolny antifungal medicines along with terfenadiny researches of interaction of these medicines were conducted. During one research at application of a flukonazol in a dose of 200 mg a day the lengthening of an interval of QTc is not revealed. Other research at application of a flukonazol in doses of 400 mg and 800 mg a day showed that application of a flukonazol in doses of 400 mg a day or above considerably increases the level of a terfenadin in blood plasma at simultaneous use of these medicines. Combined use of a flukonazol in doses of 400 mg or is higher with terfenadiny contraindicated.

Storage conditions

does not demand special storage conditions. To store out of children's reach. Not to freeze.

Expiration date - 5 years.